4035
Pharmacoeconomic analysis of immunoglobulin medicinal products efficacy for intravenous infusion in treatment of primary immunodeficiencies with antibody formation defects in the Sverdlovsk region health care system
This work included a pharmaeconomic study of the efficacy of treatment of primary immunodeficiencies (PID) with antibody formation defects using normal human immunoglobulin medicinal products for intravenous administration in the Sverdlovsk Region health care system. Four treatment regimens were compared: 10% intravenous immunoglobulin (IVIG) Privigen and 5% IVIGs Octagam, Intratect, I.G.Vena. It appeared that, from the pharmacoeconomic analysis point of view, the use of 10% normal human immunoglobulin for intravenous administration, Privigen, is the most cost-effective regimen (per patient) of primary immunodeficiency therapy among the pediatric (n=9) and adult (n=20) populations of PID patients with impaired antibody formation in the Sverdlovsk Region. In per annum terms, one pediatric patient switched to Privigen from Octagam saves 65 605 roubles; from Intratect, 183 625 roubles; from I.G.Vena, 68 949 roubles. Over the same period, one adult patient switched to Privigen from Octagam saves 170 870 roubles; from Intratect, 459 911 roubles; from I.G.Vena, 68 958 roubles. The budget impact analysis, within the Sverdlovsk Region health care system, showed that a 70% increase in Privigen procurement due to 70% reduction in Intratect procurement for PID patients helps save a total of 6 076 471 roubles per year. The lost opportunity analysis showed that the 70% increase in Privigen purchases would have provided additional funding for treatment of 11 pediatric or 3 adult PID patients with antibody formation defects.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Yagudina R.I., Beltyukov Y.K., Ugrekhelidze D.T., Skorokhodov I.S. Pharmacoeconomic analysis of immunoglobulin medicinal products efficacy for intravenous infusion in treatment of primary immunodeficiencies with antibody formation defects in the Sverdlovsk region health care system // Pharmacoeconomics: theory and practice. - 2017. - Vol.5, №3. - P.77-81 DOI: https://doi.org/10.30809/phe.3.2017.1
Comments0